Overview

A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alberta
Collaborator:
Pfizer
Treatments:
Fesoterodine
Mandelic Acids
Oxybutynin